Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VYNE Therapeutics Inc
VYNE | US
2.40
USD0.18
8.35%
VYNE | US
About VYNE Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.40
Open
2.19
High
2.42
Low
2.19
VYNE Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201 a locally administered pan-BET inhibitor soft drug to address diseases involving multiple diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202 a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114 a combination gel formation of tofacitinib and fingolimod which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater New Jersey.
View LessVYNE | US
Risk
74.1
Sharpe
-0.26
Luna's Score
61/100
Recommendation
Hold
Luna says (VYNE | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
59.5%1 month
74.1%3 months
62.1%6 months
75.4%Returns
Fundamental Ratios
PE
1.29
Fwd. PE
-
Price to book
0.43
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
1.84
Ent. to rev.
10.04
PEG
-
Other Fundamentals
EBITDA
-29.19M
MarketCap
35.40M
MarketCap(USD)
35.40M
Div. yield
-
Op. margin
-5.25K
Erngs. growth
-
Rev. growth
46.70
Ret. on equity
-60.47
Short ratio
1.57
Short perc.
0.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.62
Range1M
0.63
Range3M
0.80
Volumes: Market Activity
Rel. volume
3.88
Price X volume
533.68K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.84 | - | Expensive |
| Ent. to Revenue | 10.04 | - | Cheaper |
| PE Ratio | 1.29 | 41.03 | Cheaper |
| Price to Book | 0.43 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 62.14 | - | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 35.40M | - | Emerging |
